leadf
logo-loader
viewNeuren Pharmaceuticals Ltd
(
ASX:NEU
)

Neuren Pharmaceuticals 'in unique position' as it receives key approval for NNZ-2591 trial

Neuren Pharmaceuticals' (ASX:NEU) Jon Pilcher speaks to Proactive's Andrew Scott following the news they've received approval for the final stage of its NNZ-2591 clinical trial. The Phase 1 trial in Australia is evaluating the safety, tolerability and pharmacokinetics of the drug in healthy adult volunteers before advancing to Phase 2 trials in patients next year.

Quick facts: Neuren Pharmaceuticals Ltd

Follow
ASX:NEU

Price: 2.09 AUD

Market Cap: $266.19 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Emmerson Resources talks new high impact copper-gold drill targets at Kiola

Emmerson Resources Ltd (ASX:ERM)'s Rob Bills tells Proactive they're planning high impact drilling at the Kiola project in the Lachlan Fold Belt of NSW after a 3D MIMDAS geophysical model identified new copper-gold drill targets. The geophysical survey has been completed to assist the 2021...

1 day, 13 hours ago

2 min read